TransCode Therapeutics (RNAZ) investors approve share conversions and SEPA issuances
Rhea-AI Filing Summary
TransCode Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders with 495,162 shares of common stock present in person or by proxy, representing 52.1% of the voting power as of the May 28, 2026 record date, constituting a quorum. Stockholders approved all proposals presented.
Approvals included conversion of the Series A and Series B Preferred Stock into common stock and related issuances, conversion of the Series C Preferred Stock, and issuance of common stock under the SEPA and Convertible Notes. All director nominees were elected, an amendment to the 2021 Stock Option and Incentive Plan was approved, and WithumSmith+Brown, PC was ratified as independent registered public accounting firm for the year ending December 31, 2026. A proposal to permit adjournment of the meeting was approved but not used. Nasdaq approved the company’s Nasdaq Initial Listing Application required under Nasdaq Listing Rules 5110 and 5635(b) in connection with the share-conversion proposals.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares represented at Annual Meeting: 495,162 shares
Voting power represented: 52.1%
Series A/B conversion votes for: 143,162
+3 more
6 metrics
Shares represented at Annual Meeting
495,162 shares
Common stock present in person or by proxy at the 2026 Annual Meeting
Voting power represented
52.1%
Voting power of common stock present at the 2026 Annual Meeting
Series A/B conversion votes for
143,162
Votes for conversion of Series A and Series B Preferred Stock into common stock
Series C conversion votes for
140,517
Votes for conversion of Series C Preferred Stock into common stock
SEPA and Convertible Notes issuance votes for
108,292
Votes for issuance of common stock under the SEPA and Convertible Notes
Auditor ratification votes for
393,497
Votes for ratifying WithumSmith+Brown, PC as independent auditor for 2026
Key Terms
Series A Preferred Stock, SEPA, broker non-votes, Nasdaq Listing Rules 5110 and 5635(b), +1 more
5 terms
Series A Preferred Stock financial
"The conversion of the Series A Preferred Stock and Series B Preferred Stock into shares"
Series A preferred stock is a type of ownership share in a company that gives investors certain advantages, such as priority in receiving profits or getting their money back if the company is sold or goes bankrupt. It is often issued during early funding stages to attract investors by offering more security than common shares. This stock matters to investors because it provides a safer way to invest while still holding potential for future gains.
SEPA financial
"The issuance of Common Stock pursuant to the SEPA and Convertible Notes was approved"
SEPA, or Single Euro Payments Area, is a system that allows money to be transferred easily and quickly across European countries using a common set of rules and standards. It makes cross-border payments as simple as sending money within your own country, reducing costs and processing times. For investors, SEPA simplifies international transactions within Europe, making it easier to move funds and manage investments across multiple countries.
broker non-votes financial
"For | Against | Abstain | Broker Non-Votes 143,162 | 11,518 | 742 | 256,450"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Nasdaq Listing Rules 5110 and 5635(b) regulatory
"Nasdaq Initial Listing Application required under Nasdaq Listing Rules 5110 and 5635(b)"
Emerging growth company regulatory
"Emerging growth company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did TransCode Therapeutics (RNAZ) stockholders approve at the 2026 Annual Meeting?
Stockholders approved all proposals, including conversions of preferred stock into common, issuance of common under the SEPA and Convertible Notes, election of the full director slate, amendment of the 2021 Stock Option and Incentive Plan, and ratification of the independent auditor.
How did TransCode Therapeutics (RNAZ) investors vote on preferred stock conversions?
Stockholders approved converting Series A and Series B Preferred Stock into common stock, with 143,162 votes for, and converting Series C Preferred Stock into common stock, with 140,517 votes for, along with related common stock issuances in each case.
Which auditor did TransCode Therapeutics (RNAZ) stockholders ratify for 2026?
Stockholders ratified WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 393,497 votes for, 18,172 against, and 203 abstentions recorded on the ratification proposal.